Faisal Wahid, MD
Cardiovascular Disease · McKinney, TXNPI 1316937394
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $14,346 of the $18,189 with a category attached, or 78.9%. Eli Lilly accounts for 80.4% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2023 at $12,393 and has fallen 81.9% since, to $2,239 in 2025.
Across 200 payments — averaging $90.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$15K
- Terumo Medical Corporation$552
- Amgen$497
- Abbott$268
- Esperion Therapeutics, Inc.$239
- AstraZeneca$178
- plus $2K from 27 others
Across 468 payments — averaging $7346.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.5M
- Eli Lilly$1.1M
- Boehringer Ingelheim International GmbH$275K
- Argenx US, Inc.$170K
- Ionis Pharmaceuticals, Inc.$93K
- Novo Nordisk$93K
- plus $220K from 4 others
What the payments were for
- Travel & lodging$14,34679%
- Food & beverage$3,64520%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 67 | $14,627 |
| Terumo Medical Corporation | 5 | $552 |
| Amgen | 22 | $497 |
| Abbott | 5 | $268 |
| Esperion Therapeutics, Inc. | 7 | $239 |
| AstraZeneca | 10 | $178 |
| Medtronic | 3 | $178 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $156 |
| Boston Scientific | 6 | $155 |
| Sanofi-aventis U.S. LLC | 7 | $132 |
| Heartflow, Inc. | 4 | $112 |
| Amarin Pharma, Inc. | 6 | $109 |
| Kowa Pharmaceuticals America, Inc. | 7 | $96 |
| Pfizer | 5 | $93 |
| Novo Nordisk | 4 | $87 |
| Cleerly, Inc. | 1 | $79 |
| Impulse Dynamics (USA) Inc. | 3 | $74 |
| Biotronik Inc. | 3 | $71 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $68 |
| Cvrx, Inc. | 3 | $58 |
| Cardiovascular Systems Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Novartis | 2 | $45 |
| Boehringer Ingelheim | 2 | $38 |
| Johnson & Johnson | 2 | $33 |
| Edwards Lifesciences | 2 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Bayer | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,189 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $254,321 |
| MultaqDronedarone Hcl | 49 | $76,898 |
| XareltoRivaroxaban | 41 | $53,083 |
| BrilintaTicagrelor | 39 | $38,937 |
| Repatha SureclickEvolocumab | 11 | $11,103 |
| Ranolazine ErRanolazine | 53 | $4,656 |
| Metoprolol Succinate | 312 | $4,230 |
| ClopidogrelClopidogrel Bisulfate | 332 | $4,156 |
| Clonidine | 17 | $2,672 |
| Atorvastatin Calcium | 351 | $2,614 |
| Prasugrel Hcl | 35 | $2,185 |
| Losartan Potassium | 177 | $1,838 |
| Pitavastatin Calcium | 16 | $1,746 |
| Carvedilol | 195 | $1,723 |
| Valsartan | 37 | $1,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $254,321230 claims |
| Sanofi-aventis U.S. LLCMultaq | $132 | $76,89849 claims |
| Johnson & JohnsonXarelto | $33 | $53,08341 claims |
| AstraZenecaBrilinta | $178 | $38,93739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in McKinney
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.